{"id":"W3194157976","doi":"10.1016/j.jtct.2021.08.007","title":"Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes","year":2021,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; U.S. Public Health Service; Health Resources and Services Administration; CytoSen Therapeutics; Kiadis Pharma; Pfizer; Incyte; Kyowa Kirin Pharmaceutical Development; Jazz Pharmaceuticals; Medical College of Wisconsin; Takeda Pharmaceuticals U.S.A.; Meso Scale Diagnostics; AbbVie; National Cancer Institute; Gilead Sciences; Karyopharm Therapeutics; Celgene; Novartis; GlaxoSmithKline; Otsuka America; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Falk Foundation; CareDx; Daiichi-Sankyo","keywords":"Medicine; Fludarabine; Busulfan; Melphalan; Alemtuzumab; Internal medicine; Transplantation; Regimen; Hematopoietic stem cell transplantation; Cumulative incidence; Incidence (geometry); Surgery; Gastroenterology; Oncology; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004440839,0.0001596252,0.0002933356,0.0001556495,0.0001136472,0.0001577908,0.0001011201,0.0001800407,0.000593657],"category_scores_gemma":[0.0009381952,0.00005604172,0.0003378928,0.0001044963,0.000110359,0.0001827884,0.000173612,0.000235403,0.00006541914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001803797,"about_ca_system_score_gemma":0.0001572517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004293462,"about_ca_topic_score_gemma":0.001570445,"domain_scores_codex":[0.9998658,0.0000525487,0.00001747626,0.00001541263,0.00002091268,0.00002788635],"domain_scores_gemma":[0.9996452,0.00007286727,0.0001357592,0.000009078599,0.00001109085,0.0001259646],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.07882463,0.0029577,0.6921977,0.000418927,0.001114,0.0005291129,0.0003224927,0.001251935,0.01335597,0.0001429141,0.001322459,0.2075621],"study_design_scores_gemma":[0.004270408,0.04065147,0.9498543,0.00006408012,0.0006000244,0.000757358,0.000174156,0.001014809,0.001175677,0.0001299079,0.001295035,0.00001280491],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9990525,0.0007295159,0.00001654069,0.00004958589,0.0000102614,0.000004487662,0.00001341955,0.000002039278,0.0001216222],"genre_scores_gemma":[0.9995661,0.0002037625,0.00004755771,0.00005465596,0.00002395691,0.00000474163,0.00004333442,3.412941e-7,0.00005549422],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.000593657,"threshold_uncertainty_score":0.002348542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01111338953044004,"score_gpt":0.245643071941076,"score_spread":0.234529682410636,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}